Amoeba SA (FR:ALMIB)
:ALMIB
Want to see FR:ALMIB full AI Analyst Report?
ALMIB Stock Chart & Stats
€1.08
-€0.01(-1.20%)
At close: 4:00 PM EST
€1.08
-€0.01(-1.20%)
Day’s Range― - ―
52-Week Range€0.78 - €1.36
Previous CloseN/A
Volume10.38K
Average Volume (3M)268.33K
Market Cap
€69.93M
Enterprise Value€77.44M
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding77,817,220
10 Day Avg. Volume303,333
30 Day Avg. Volume268,330
Financial Highlights & Ratios
PEG Ratio1.14
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Proprietary IPOwning a unique microorganism provides a durable product differentiation and potential regulatory/market exclusivity across applications. This IP can support long-term licensing, defendable product positioning and higher barriers to entry if commercialized and registered in target markets.
Market DiversificationServing both agricultural crop protection/biostimulant and industrial water/microbial-control markets spreads commercial risk across end markets. Durable multi-market exposure enables different revenue cycles, channel strategies and use cases, improving resilience once products scale.
Scalable Go-to-Market ModelA business model that combines direct sales, territorial distribution deals and licensing supports scalable growth with lower fixed capital needs. Durable partner-led commercialization can accelerate market access and enable royalty streams without large manufacturing capex if partnerships materialize.
Bears Say
Revenue CollapseA complete collapse of revenue is a structural red flag: it prevents leveraging fixed costs, halts organic reinvestment, and undermines credibility with distributors and regulators. Absent sustained sales, product validation and long-term commercial viability are highly uncertain.
Negative Equity & Rising DebtPersistent negative equity and materially higher leverage reduce financial flexibility and raise refinancing risk. This structural balance sheet weakness limits the company's ability to fund registrations, scale production or absorb shocks without dilutive or costly financing.
Persistent Cash BurnConsistently negative operating and free cash flow indicates reliance on external funding to sustain operations. Structurally, this constrains investment in commercialization and regulatory dossiers, increases dilution risk, and makes long-term execution contingent on securing reliable financing.
Amoeba SA News
ALMIB FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest stock price was €0.78 and its highest was €1.36 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €69.93M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Sep 24, 2026 which is in 127 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Mar 26, 2026. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.066.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 77,817,220 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.112%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in FR:ALMIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. develops and sells biocidal and fungicide products. It is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds, and plant protection. The company was founded in 2010 and is headquartered in Chassieu, France.
Technical Analysis
Options Prices
Currently, No data available
---